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Milan, and Naples, ItalyObjectives This study sought to assess the usefulness of clopidogrel-pathway genotyping and on-
treatment platelet reactivity (OTR) testing in predicting major adverse cardiac events (MACE) in stable
coronary artery disease (CAD) patients receiving drug-eluting stents (DES) under dual antiplatelet
(clopidogrel plus aspirin) therapy.
Background The role of pharmacogenetics and OTR in predicting MACEddeath, myocardial
infarction, or stent thrombosisdin stable CAD patients scheduled for DES implantation is still debated.
Methods Patients with stable CAD treated by DES implantation (n ¼ 1,432) were genotyped with
a TaqMan OpenArray (Applied Biosystems, Carlsbad, California) and assessed for OTR with the
VerifyNow P2Y12 test (Accumetrics Inc., San Diego, California). Genes tested were ABCB1, CYP1A2,
CYP2B6*9, CYP2C8*3, CYP2C9*2, CYP2C19, CYP3A4, CYP3A5*3, P2RY12, and PON1CYP2C19. High OTR was
deﬁned as P2Y12 reaction units 230. The endpoint at 12-month follow-up was MACE occurring during
antiplatelet therapy.
Results All groups that were stratiﬁed for loss-of-function variants of the cytochrome P450 gene
CYP2C19 had signiﬁcant hazard ratios (HR) for MACE (genotypic HR: 1.41, 95% conﬁdence interval [CI]:
1.06 to 1.89, p ¼ 0.01; allelic HR: 1.56, 95% CI: 2.26 to 1.2, p ¼ 0.01). Variants of other clopidogrel-
pathway genes were not signiﬁcantly associated with MACE. When OTR was assessed, clinical
signiﬁcance was found only in high-risk diabetic (HR: 2.11, 95% CI: 1.29 to 3.45, p < 0.001) and chronic
kidney disease (HR: 2.03, 95% CI: 1.03 to 4.02, p ¼ 0.04) patients.
Conclusions CYP2C19 metabolizer status is an independent predictor of MACE after DES implantation
and can be used for prognostication in all stable CAD patients. High OTR, as assessed by the VerifyNow
P2Y12 test, is an independent predictor of MACE only for high-risk subsets, that is, patients with
diabetes or chronic kidney disease. (J Am Coll Cardiol Intv 2013;6:1166–75) ª 2013 by the American
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Abbreviations
and Acronyms
CAD = coronary artery
disease
CKD = chronic kidney
disease
CYP = cytochrome P450
DES = drug-eluting stent(s)
DM = diabetes mellitus
HR = hazard ratio(s)
LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac events
OTR = on-treatment platelet
reactivity
P2Y12 = purinergic receptor
P2Y, G-protein coupled, 12
PRU = P2Y12 reaction units
SNP = single-nucleotide
polymorphism
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1167Clopidogrel is administered with aspirin for dual antiplatelet
therapy of coronary artery disease (CAD) (1). Despite the
proven efﬁcacy of clopidogrel, interindividual variability in
drug action signiﬁcantly inﬂuences therapeutic outcome
(2,3). In fact, being a prodrug, clopidogrel requires modiﬁ-
cation into a thiol metabolite within the liver before acquiring
full activity (4), so the efﬁcacy of clopidogrel’s antiaggrega-
ting effect depends on pharmacodynamic factors related to
drug-metabolizing enzymes, such as the cytochrome P450
(CYP) family members (e.g., CYP1A2, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP3A4, and CYP3A5) and para-
oxonase 1 (PON1), the transport molecule mediating the
drug’s uptake by intestinal cells (i.e., adenosine triphospha-
tase–binding cassette, subfamily B [MDR/TAP], member
1, or ABCB1), and its molecular target on platelets (i.e., the
purinergic receptor P2Y, G-protein coupled, 12, or P2Y12)
(5–8).
Following percutaneous revascularization, the rate of major
adverse cardiac events (MACE), such as stent thrombosis,
myocardial infarction, or death, is signiﬁcantly increased in
those patients presenting with high on-treatment platelet
reactivity (OTR) (3,9,10). Currently, there are 2 major
approaches to identifying high-risk patients: the ﬁrst assesses
themetabolizing status, which involves genotyping to uncover
single-nucleotide polymorphisms (SNP) that have a negative
impact on the bioactivation of clopidogrel; the other entails
the response status and refers to functional phenotypic testing
to measure residual platelet reactivity in peripheral whole
blood. However, it is not yet clear which is the more reliable
method of MACE prognostication. We therefore decided to
evaluate these 2 approaches for predicting the occurrence of
12-month MACE following deployment of drug-eluting
stents (DES) in patients with stable CAD and on dual anti-
platelet therapy.
Methods
Study population. All consecutive patients scheduled
between January 7, 2008 and January 31, 2010 to undergo
elective DES implantation at the Clinica Mediterranea
(Naples, Italy) were assessed for their suitability for the
study. Exclusion criteria were: either non–ST-segment or
ST-segment elevation myocardial infarction; cardiogenic
shock; allergy/intolerance to aspirin and/or clopidogrel;
ongoing serious bleeding or bleeding diathesis; platelet
count 75.000/mm3; planned or undelayable noncardiac
surgery; previous percutaneous coronary intervention or
coronary artery bypass grafting; severe liver disease (e.g.,
cirrhosis or portal hypertension); and life expectancy <1 year
due to other medical conditions. All enrolled patients
gave informed consent prior to the index procedure. Dia-
betes mellitus (DM) was diagnosed according to current
guidelines (11). Chronic kidney disease (CKD) was deﬁned
as an estimated glomerular ﬁltration rate <60 ml/min/1.73 m2 (12). This study was approved by the local ethics
committees.
Stenting procedure and pharmacological approach. At the
discretion of the operator, either intraprocedural unfractio-
nated heparin (goal-activated clotting time >250 s) or
bivalirudin was used before the procedure. Tiroﬁban (a
glycoprotein IIb/IIIa inhibitor) was administered according
to the operator’s judgment. All patients received at least 1
DES. Either ﬁrst-generation (Cypher Select [Cordis,
Johnson & Johnson, Miami Lakes, Florida]; Taxus Libertè
[Boston Scientiﬁc Corporation, Natick, Massachusetts]) or
second-generation (Endeavor Resolute or Resolute Integrity
[Medtronic CardioVascular, Santa Rosa, California]; Pro-
mus or Promus Element [Boston Scientiﬁc]; Nobori [Ter-
umo, Tokyo, Japan]) DES were implanted. Patients received
aspirin (100 mg daily) and clo-
pidogrel (75 mg daily) before
stent deployment. In patients not
already on therapy, a clopidogrel
loading dose of 600 mg was
administered the day before the
procedure.
Post-procedure management and
follow-up. Dual antiplatelet
therapy, consisting of the
administration of aspirin (100
mg/day) and clopidogrel (75 mg/
day) for at least 12 months, was
prescribed to all patients. In
patients deemed at high risk
(including those with DM,
CKD, multivessel CAD, chronic
total occlusion, or bifurcation
lesions), clopidogrel administra-
tion was recommended for more
than 12 months. Clinical follow-
up was performed via a visit to
the outpatient clinic or by a tele-
phone interview with the patient at 1 month and, thereafter,
every 3 months until the 12th month. If clopidogrel was
discontinued before the recommended period, the date of
discontinuation was recorded.
Platelet reactivity assay. The inhibitory effect of clopidogrel
on platelet aggregation was measured with the VerifyNow
P2Y12 test (Accumetrics Inc., San Diego, California) (13)
within 24 h of DES deployment. Speciﬁcally, the test was
performed in all instances on the morning following DES
implantation, within 3 h of the last maintenance dose of
clopidogrel. In patients receiving periprocedural tiroﬁban,
the test was performed at least 48 h after drug discontinua-
tion. OTR was assessed after, rather than before, stent
implantation for the following reasons: 1) it was not the
purpose of the present study to assess the relationship
between OTR and periprocedural myocardial infarction; 2)
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operator’s decision to use glycoprotein IIb/IIIa inhib-
itors and/or an additional loading dose of clopidogrel; and
3) it would have led to the direct exclusion of patients
treated with balloon angioplasty rather than with stent
implantation.
The VerifyNow P2Y12 test is a rapid, point-of-care,
cartridge-based, platelet-function assay designed to directly
measure the blockade of drugs on the P2Y12 receptor (13).
The level of platelet aggregation is measured as an increase
in light transmittance as activated platelets bind and ag-
gregate ﬁbrinogen-coated beads. A proprietary algorithm
is used to report values in P2Y12 reaction units (PRU). A
PRU 230 reﬂects greater platelet reactivity and was used
to deﬁne patients with high OTR (10). In a secondary
analysis, a PRU >208 was also used to deﬁne patients with
high OTR (14).
DNA extraction, selection of SNP, and genotyping. After
DES deployment, 4 ml whole peripheral blood was obtained
from patients, the genomic deoxyribonucleic acid (DNA)
extracted from mononuclear cells with the DNA QIAamp
Midi kit (Qiagen Inc., Valencia, California) according to the
manufacturer’s instructions, and the DNA stored at –20C
until used. The quantity and quality of the genomic
DNA were veriﬁed with a NanoDrop spectrophotometer
(Thermo Fisher Scientiﬁc, Waltham, Massachusetts) before
being assayed with the TaqMan OpenArray Genotyping
System (Applied Biosystems, Carlsbad, California).
The clopidogrel-metabolizing pathway SNPs used in
the customized genotyping panel were: ABCB1 (rs1045642);
CYP1A2 (rs762551); CYP2B6*9 (rs3745274); CYP2C8*3 (rs
10509681); CYP2C9*2 (rs1799853); CYP2C19*2 (rs42
44285); CYP2C19*3 (rs4986893); CYP2C19*4 (rs28399504);
CYP2C19*5 (rs56337013); CYP2C19*17 (rs12248560);
CYP3A4 (rs2242480, rs4986910); CYP3A5*3 (rs776746);
P2RY12 (rs2046934); and PON1 (rs854560, rs662) (15,16).
Sample processing was fully automated using the Freedom
EVO150 robotic workstation (Tecan Group Ltd., Män-
nedorf, Switzerland). Fluorescent signals were recorded by
the OpenArray instrument, and speciﬁc cluster parameters
were automatically obtained to precisely assign the relative
genotypes. All samples were genotyped in duplicate to verify
the results and avoid technical errors. All patients were
stratiﬁed according to genotype effect on clopidogrel
metabolism (extensive, intermediate, and poor metabo-
lizers). For CYP2C19, patients were classiﬁed as: 1) extensive
metabolizers, for individuals not carrying a loss-of-function
variant (*1*1) or for carriers of at least 1 increased enzymatic-
activity allele (*1*17 or *17*17); 2) intermediate metabolizers,
for carriers of 1 loss-of-function allele (*1*2, *1*3, *1*4, or
*1*5); 3) poor metabolizers, for carriers of 2 loss-of-function
alleles (*2*2, *2*3, *2*4,*2*5*, *3*3, *3*4, *3*5*, *4*5, etc.); or 4)
unknown metabolizers, for patients presenting with 1 loss-
of-function allele plus a *17 allele.Study endpoints. The primary endpoint of the study was
on-treatment MACE, deﬁned as cardiac death, nonfatal
myocardial infarction, or stent thrombosis during clopi-
dogrel treatment. Therefore, each patient was censored
once off clopidogrel. Myocardial infarction during follow-
up was deﬁned as any typical change in cardiac biomarkers
in conditions associated with cardiac ischemia, according to
American College of Cardiology guidelines (17). Stent
thrombosis was deﬁned according to Academic Research
Consortium criteria (18). An independent medical com-
mittee assigned and recorded all occurrences of MACE.
MACE rate was stratiﬁed according to OTR and
genotype.
Statistical analyses. The choice of sample size was based on
the assumptions of: 1) an annual MACE rate >10%; and 2)
a high OTR occurrence in 30% of patients. These
assumptions were derived from the data available in the
literature (14,19–21). Continuous selected variables are
given as mean  SD. Normality assumption was veriﬁed
graphically (i.e., QQ plot) and was conﬁrmed using the
Shapiro-Wilk test. Categorical variables are expressed in
percentages. Comparisons between groups were performed
by Student t test or chi-square test. The percentage of
successfully genotyped samples and the average genotyping
success rate for each SNP (>85%) were calculated; Hardy-
Weinberg equilibrium was determined using the chi-square
goodness-of-ﬁt test. Initially, to examine the effects of the
selected SNP and of PRU 230, t test and 1-way analysis
of variance were employed. Survival curves were generated
using Kaplan-Meier product limit estimator. Unadjusted
comparisons between predicted functional groups deﬁned
by PRU 230 versus <230 or by genotyping (e.g.,
CYP2C19-based metabolizer status) and the composite
MACE outcomes were compared using log-rank test. The
presence of at least 1 of the following criteria identiﬁed
patients at high risk: DM; CKD; age >75 years; multivessel
disease; and left ventricular ejection fraction (LVEF) <40%
(22–30). Cox proportional hazards model was used to
provide hazard ratios (HR) with 95% conﬁdence intervals
and adjustment for previously selected clinical predictors
(selected a priori by the clinician according to the features of
our patient population and to p < 0.01 at univariate anal-
ysis), including: age; LVEF; sex; DM; smoking; number of
diseased coronary arteries; DES type; estimated glomerular
ﬁltration rate; chronic total occlusion; and CKD. To correct
for multiple testing, 1,000 bootstrap iterations were
computed. The area under the receiver-operating charac-
teristic curve (AUC) was ﬁnally used to determine the
discriminatory ability of the model. AUC is the probability
that a randomly selected patient with the event had
a predicted probability of event higher than that of
a randomly selected patient without the event. A value of 1
denotes perfect discrimination, whereas a value of 0.5 is
no better than chance. For all tests, p<0.05 was considered
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1169statistically signiﬁcant. Statistical analyses were performed
with the Stata program (version 11/SE, StataCorp LP,
College Station, Texas).
Results
Study population. A complete clinical follow-up was avail-
able for 1,432 of 1,461 (98%) patients. MACE at follow-
up occurred in 114 (7.9%) patients. Speciﬁcally, cardiac
death occurred in 14 (0.9%) patients, nonfatal myocardial
infarction in 49 (3.4 %), and stent thrombosis in 51 (3.5%)
patients (deﬁnite 1.0%, n ¼ 14; probable 1.7%, n ¼ 25;
possible 0.8%, n ¼ 12). Clinical, angiographic, and proce-
dural features of patients with MACE (MACE group) and
without MACE (event-free group) are summarized in
Tables 1 and 2. The MACE group had higher percentages
of individuals with LVEF <40%, CKD, DM, or chronic
total occlusion than did the event-free group. The majority of
patients (89.3%) in the 2 groups received second-generation
DES. The median duration of dual antiplatelet therapy was
20 (range 15 to 26) months. Dual antiplatelet therapy lasted
>1 year in 70% of the MACE group and in 69.2% of the
event-free group (p ¼ 0.87).Table 1. Clinical Features at Baseline of the Global and M
Global
(n ¼ 1,432)
General characteristics
Age, yrs 64.9  10.2
Body mass index, kg/m2 27.9  4.3
Male 1,107 (77.7)
Current smokers 385 (26.9)
LVEF, % 52.4  8.45
Blood biochemistry
Cholesterol, mg/dl 161.2  43.9
High-density lipoprotein, mg/dl 52.2  28.0
Low-density lipoprotein, mg/dl 88.0  37.7
Triglycerides, mg/dl 109.3  73.1
Therapy
Clopidogrel MD 379 (26.5)
Statins 1,260 (87.9)
Proton-pump inhibitor 693 (48.4)
Calcium-channel blocker 358 (25.0)
Glycoprotein IIb/IIIa inhibitor 12 (0.8)
Comorbidities
LVEF <40% 153 (10.7)
CKD 332 (23.2)
Diabetes mellitus 572 (39.9)
Hypertension 1,048 (73.2)
MVD 1,006 (70.2)
Values are mean  SD or n (%). Clopidogrel maintenance dose refers to
implantation. In patients not already on therapy, a clopidogrel loading do
CKD ¼ chronic kidney disease; LVEF ¼ left ventricular ejection fraction
MVD ¼ multivessel disease.Response status and metabolizing status as MACE predictors
within the whole population. As assessed by the VerifyNow
P2Y12 test, 40.5% (584 of 1,432) of patients had a PRU
230. No signiﬁcant interactions were observed between
response status and other drugs metabolized by cytochrome
P450 (namely, statins, proton-pump inhibitors, and
calcium-channel blockers). Durations of dual antiplatelet
therapy were 20 (range 13.5 to 26.5) months in patients
with PRU 230 and 19 (range 12 to 25) months in
patients with PRU <230 (p ¼ 0.15). Genotyping was
successful in 1,432 patients (>85%). Intermediate metab-
olizers represented 27% of the total population, whereas
poor metabolizers comprised 4.7%. In detail, the high-
OTR group (i.e., with a PRU 230) was composed of
28.3% intermediate metabolizers and 6.7% poor metabo-
lizers. On the contrary, the low-OTR group (PRU <230)
was composed of 27.5% intermediate metabolizers and 3.5%
poor metabolizers. The analysis of CYP2C19 genotype
distribution revealed a higher percentage of poor metabo-
lizers in the MACE group (Table 3). A signiﬁcant associa-
tion with absolute PRU values was observed in CYP2C19
metabolizer classes at the genotypic (1-way analysis of vari-
ance, p< 0.02) and allelic (1-tailed student t test, p< 0.001)ACE-Stratiﬁed Populations
Event-Free Group
(n ¼ 1,318)
MACE Group
(n ¼ 114) p Value
64.8  10.2 65.3  9.8 0.67
27.9  4.4 27.5  3.7 0.24
1,024 (77.7) 83 (72.8) 0.24
354 (26.8) 31 (27.2) 0.34
52.5  8.37 51.5  9.35 0.31
161.5  43.9 162.2  43.9 0.43
52.3  28.4 48.7  27.0 0.10
87.7  38.1 91.5  35.9 0.16
108.6  73.4 116.3  70.8 0.14
355 (27.0) 24 (21.0) 0.15
1,164 (88.3) 96 (84.2) 0.08
639 (48.5) 54 (47.3) 0.40
330 (25.0) 28 (24.5) 1.00
12 (0.9) 0.0 0.61
131 (9.9) 22 (19.3) 0.01
289 (21.9) 43 (37.7) <0.001
511 (38.7) 61 (53.5) <0.001
966 (73.2) 82 (71.9) 0.73
912 (69.2) 94 (82.4) <0.001
patients already treated with clopidogrel before drug-eluting stent
se of 600 mg was administered the day before the procedure.
; MACE ¼ major adverse cardiac events; MD ¼ maintenance dose;
Table 2. Angiographic and Procedural Features of the Global and MACE-Stratiﬁed Populations
Global
(n ¼ 1,432)
Event-Free Group
(n ¼ 1,318)
MACE Group
(n ¼ 114) p Value
Second-generation DES type 1,279 (89.3) 1,204 (91.3) 75 (65.8) 0.17
Stent length, mm 28.2  12.3 28.0  12.4 27.5  11.2 0.31
Stents per patient 1.45  0.79 1.44  0.78 1.53  0.92 0.63
Complex lesion, B2/C 855 (59.7) 787 (59.7) 68 (59.6) 0.86
Chronic total occlusion 156 (10.9) 136 (10.3) 20 (17.5) 0.01
Bifurcation lesion 281 (19.6) 258 (19.6) 23 (20.2) 0.88
Minimal lumen diameter, mm
Pre-procedure 0.51  0.39 0.51  0.38 0.52  0.3 0.96
Post-procedure 3.24  0.57 3.25  0.57 3.19  0.51 0.28
Reference vessel diameter, mm
Pre-procedure 3.12  0.56 3.13  0.56 3.03  0.48 0.08
Post-procedure 3.29  0.54 3.29  0.54 3.28  0.40 0.78
Maximal inﬂation pressure, atm 19.0  4.96 19.0  4.92 19.1  5.40 0.89
Balloon-to-artery ratio 1.05  0.16 1.05  0.13 1.06  0.35 0.51
Values are n (%) or mean  SD.
DES ¼ drug-eluting stent(s); MACE ¼ major adverse cardiac events.
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1170levels. No signiﬁcant differences were found between the
MACE group and the event-free group when OTR and the
other analyzed SNPs of the clopidogrel pathway were
considered (Table 3).
Table 4 reports log-rank estimates for the phenotypic
and genetic tests. Consistent associations at the genotypic
and allelic levels were found only for CYP2C19 variants; in
fact, log-rank test for MACE-free survival showed high-
er MACE rates in poor and intermediate metabolizers with
respect to extensive metabolizers (Table 4, Figs. 1A and 1B).Table 3. Summary of Distributions of Patients According t
Test Comparison
Event-Free
(n ¼ 1,3
OTR* Low vs. high OTR 778/540
CYP2C19 variantsy EM vs. IM vs. PM 855/347/58
ABCB1 (3,435 C>T) CC vs. CT vs. TT 346/597/275
CYP1A2*1F (164 A>C) AA vs. AC vs. CC 577/516/155
CYP2B6*9 (516 G>T) GG vs. GT vs. TT 602/424/98
CYP2C8*3 (416 G>A) GG vs. GA vs. AA 948/267/36
CYP2C9*2 (430 C>T) CC vs. CT vs. TT 986/236/16
CYP3A4 (20,239 G>A) GG vs. GA vs. AA 898/232/18
CYP3A4 (1,334 T>C) TT vs. TC vs. CC 1235/8/0
CYP3A5*3 (6,986 A>G) AA vs. AG vs. GG 1096/140/6
P2RY12 (744 T>C H1H2)z TT vs. TC vs. CC 1041/204/6
PON1 (260 T>A) TT vs. TA vs. AA 521/534/159
PON1 (672 A>G) AA vs. AG vs. GG 599/547/103
The p values were calculated with Pearson statistic. p, Allele are p values ob
reaction units <230. *On-treatment platelet reactivity, assessed by the Ve
G>A), CYP2C19*3 (636 G>A), CYP2C19*4 (1 A>G), CYP2C19*5 (1,297 C>T),
tagged by rs2046934, rs10935838, rs5853517, and rs6809699.
EM ¼ extensive metabolizers; IM ¼ intermediate metabolizers; MACE ¼
PM ¼ poor metabolizers; SNP ¼ single nucleotide polymorphism.No signiﬁcant association was observed between MACE
and high OTR or the other tested SNPs (Table 4, Fig. 1C).
No signiﬁcant association was found when considering
a different PRU cutoff (208) (Online Table 1).
Univariate and multivariate Cox proportional hazards
models were used to provide corrected HRs for both the
response status and the metabolizing status. The following
independent variables were included in the Cox regression
as potential factors affecting composite outcome: age; sex;
smoking; DES type; DM; CKD; LVEF <40%; ando OTR and SNP
Group
18)
MACE Group
(n ¼ 114) p Value p, Allele
(59/41) 70/44 (61/39) 0.63
(68/27/5) 64/39/10 (57/34/9) 0.02 <0.001
(28/49/23) 24/56/26 (23/53/24) 0.44 0.28
(46/41/13) 44/50/16 (40/45/15) 0.44 0.21
(53/38/9) 56/39/6 (55/39/6) 0.63 0.47
(76/21/3) 88/20/3 (79/18/3) 0.70 0.44
(80/19/1) 92/15/1 (85/14/1) 0.38 0.18
(78/20/2) 76/23/3 (74/23/3) 0.48 0.28
(99/1/0) 109/0/0 (100/0/0) 0.40 0.40
(88/11/1) 91/18/1 (83/16/1) 0.22 0.10
(83/16/1) 89/20/1 (81/18/1) 0.72 0.49
(43/44/13) 43/47/13 (42/46/12) 0.94 0.92
(48/44/8) 57/43/9 (52/40/8) 0.66 0.50
tained in allelic status. High ¼ P2Y12 reaction units 230. Low ¼ P2Y12
rifyNow P2Y12 test. yComposite of CYP2C19 variants: CYP2C19*2 (681
and CYP2C19*17 (806 C>T). zH1H2 haplotype (H2 minor haplotype)
major adverse cardiac events; OTR ¼ on-treatment platelet reactivity;
Table 4. Log-Rank Test for All CAD Patients
Test Comparison p Value p, Allele
OTR* Low vs. high 0.08
CYP2C19 variantsy EM vs. IM vs. PM 0.01 <0.00
ABCB1 (3,435 C>T) CC vs. CT vs. TT 0.11 0.70
CYP1A2*1F (–164 A>C) AA vs. AC vs. CC 0.40 0.39
CYP2B6*9 (516 G>T) GG vs. GT vs. TT 0.73 0.70
CYP2C8*3 (416 G>A) GG vs. GA vs. AA 0.48 0.40
CYP2C9*2 (430 C>T) CC vs. CT vs. TT 0.24 0.10
CYP3A4 (20,239 G>A) GG vs. GA vs. AA 0.16 0.08
CYP3A4 (1,334 T>C) TT vs. TC vs. CC 0.12 0.20
CYP3A5*3 (6,986 A>G) AA vs. AG vs. GG 0.29 0.14
P2RY12 (744 T>C H1H2)z TT vs. TC vs. CC 0.68 0.67
PON1 (260 T>A) TT vs. TA vs. AA 0.97 0.97
PON1 (672 A>G) AA vs. AG vs. GG 0.71 0.71
The p values were calculated by log-rank for genetic analysis and adjusted for bootstrap
sampling method. p, Allele are p values obtained in allelic status. *On-treatment platelet
reactivity, assessed by the VerifyNow P2Y12 test. yComposite of CYP2C19 variants: CYP2C19*2
(681 G>A), CYP2C19*3 (636 G>A), CYP2C19*4 (1 A>G), CYP2C19*5 (1,297 C>T), and CYP2C19*17
(806 C>T). zH1H2 haplotype (H2 minor haplotype) tagged by rs2046934, rs10935838,
rs5853517, and rs6809699.
CAD ¼ coronary artery disease; other abbreviations as in Table 3.
Figure 1. Kaplan-Meier Curves for MACE-Free Survival
Patients were stratiﬁed based on CYP2C19 metabolizer status (A), allelic level
(B), or on-treatment platelet reactivity (C). EM ¼ extensive metabolizers; IM ¼
intermediate metabolizers; MACE ¼ major adverse cardiac events; PM ¼ poor
metabolizers; PRU ¼ P2Y12 reaction units.
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1171multivessel disease. Treatments with statins, proton-pump
inhibitors, and/or calcium-channel blockers were not
included because the role as clinical predictors was not
signiﬁcant.
We found that MACE rate was higher in carriers of loss-
of-function CYP2C19 alleles (patients classed as either
intermediate or poor metabolizers) than in noncarriers
(extensive metabolizer patients) (Table 5). The HR
computed for the other analyzed SNP did not reveal
signiﬁcant differences for MACE occurrence (Online
Tables 2 and 3). There was no signiﬁcant difference in
MACE rates when patients were stratiﬁed according to the
PRU cutoff (Table 5).
To evaluate the prognostic ability of both the response
status and the metabolizing status, multivariate logistic
regression was undertaken ﬁrst with clinical predictors alone
and then including both genetic and OTR variables. AUC
was 0.682 when considering only clinical predictors, slightly
increased (0.701, p ¼ 0.18) when genetic assay predictors
were included, and unchanged (0.683, p ¼ 0.51) with OTR
assay predictor. Results identical to those of the whole
population were found after excluding patients who received
tiroﬁban (Online Tables 4 to 7).
Response status and metabolizing status as MACE predictors
in subgroups at high risk. The predictive accuracies of the
OTR and of CYP2C19-based metabolizer stratiﬁcation were
further assessed with the log-rank test in the high-risk
subgroups of patients (i.e., those with DM, CKD, age >75
years, multivessel disease, or LVEF<40%). To obviate the
low effect size caused by low frequency of composite
cardiovascular events, CYP2C19-based categories wereconsidered only in allelic status. The p values were calculated
for each analyzed class (phenotypic and genetic). CYP2C19-
based metabolizer stratiﬁcation was conﬁrmed to have
prognostic value for MACE in all high-risk groups (Table 6,
Figs. 2A and 2B). However, the OTR-based assay had
prognostic value only for diabetic and CKD patients
(Table 6, Figs. 3A and 3B). Similarly, univariate and
multivariate Cox regression exhibited signiﬁcant HR values
for CYP2C19- and OTR-based assays in patients
Table 5. Univariate and Multivariate Cox Proportional Hazard Ratios
for OTR- and CYP2C19-Based Predictive Tests in All Patients
Comparison
Univariate Model Multivariate Model
HR 95% CI p Value HR 95% CI p Value
OTR* Low vs. high 1.02 0.7–1.49 0.90 1.34 0.84–2.11 0.20
CYP2C19
variantsy
EM vs. IM vs. PM 1.41 1.06–1.89 0.01 1.38 1.01–1.91 0.04
EM vs. (IM þ PM) 1.56 1.26–2.26 0.01 1.58 1.04–2.38 0.03
For the adjusted p values, bootstrap samplingmethod (1000 reps) was employed. *On-treatment
platelet reactivity, assessed by the VerifyNow P2Y12 test. yComposite of CYP2C19 variants:
CYP2C19*2 (681 G>A), CYP2C19*3 (636 G>A), CYP2C19*4 (1 A>G), CYP2C19*5 (1,297 C>T), and
CYP2C19*17 (806 C>T).
CI ¼ conﬁdence interval(s); HR ¼ hazard ratio(s); other abbreviations as in Table 3.
Figure 2. Kaplan-Meier Curves of MACE-Free Survival for CYP2C19
Metabolizer Groups
Survival in patients copresenting with diabetes mellitus (A) or chronic kidney
disease (B). Abbreviations as in Figure 1.
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1172copresenting with DM or CKD (Table 7). Potential inter-
action effects evaluated in a subset population were not
signiﬁcant.
In diabetic patients, the AUCs were 0.642 with clinical
predictors, 0.665 (p ¼ 0.68) with metabolizer predictors,
and 0.652 (p ¼ 0.73) with the OTR. In CKD patients, the
AUC was 0.717 for clinical predictors, 0.748 (p ¼ 0.47)
when including CYP2C19 genotyping variables, and 0.727
(p ¼ 0.78) for the phenotypic predictors. The prognostic
values of both response and metabolic status in diabetic
patients according to the treatment (insulin versus no
insulin), and in CKD patients according to the presence of
DM, are reported as supplementary data (Online Table 8),
as is the impact of second-generation DES (Online Tables
9 to 11).
Discussion
Two major ﬁndings of the present study applying to patients
with stable angina are: 1) routine assessment of CYP2C19
polymorphisms can be used to risk-stratify stable CAD
patients receiving DES; and 2) routine assessment of OTR
with the VerifyNow P2Y12 test has a predictive value only in
high-risk (diabetic or CKD) patients.
Prognostication of MACE with genotyping. The present
study strengthens the concept that the genetic status ofTable 6. Log-Rank Test in High-Risk Subsets of Patients
High OTR* CYP2C19 Variantsy
Diabetes mellitus 0.01 0.02
CKD 0.03 0.02
Age >75 yrs 0.81 0.03
Multivessel disease 0.53 0.04
LVEF <40% 0.96 0.04
*On-treatment platelet reactivity, assessed by the VerifyNow P2Y12 test (P2Y12 reaction units
230). yComposite of CYP2C19 variants: CYP2C19*2 (681 G>A), CYP2C19*3 (636 G>A),
CYP2C19*4 (1 A>G), CYP2C19*5 (1,297 C>T), and CYP2C19*17 (806 C>T).
Abbreviations as in Tables 1 and 3.CYP2C19 can be used to predict the occurrence of MACE
after stenting in stable CAD patients (6,7,31–34). In
agreement with Mega et al. (35), the results of the current
study support the notion that carrying at least 1 loss-of-
function CYP2C19 allele increases the risk of MACE.
Indeed, intermediate and poor metabolizer categories of
patients were found singularly or in a combined manner
(allelic status) to be associated with a higher occurrence of
MACE during clopidogrel therapy (7,35). CYP2C19 is
a highly polymorphic gene that is critical for 2 essential
oxidative steps of clopidogrel bioactivation (4). The clinical
consequences of decreased clopidogrel activation due to
deleterious effects of CYP2C19 variants have been exten-
sively described (6,31–33). In addition, our study also agrees
with others reporting that polymorphisms in ABCB1,
CYP1A2, CYP2B6*9, CYP2C8, CYP2C9*2, CYP3A4,
CYP3A5*3, P2RY12, or PON1 are not statistically associated
with increased risk of MACE (6,36–38).
Prognostication of MACE with the VerifyNow P2Y12 test. Our
data extend and clarify the current knowledge on the
potential clinical beneﬁt of assessing OTR in patients
scheduled for elective DES implantation. When dealing
with stable CAD patients with an expected overall low
Figure 3. Kaplan-Meier Curves of MACE-Free Survival Stratiﬁed for
Clopidogrel Reactivity
Survival in diabetic patients (A) and chronic kidney disease patients (B)
stratiﬁed into phenotypic groups based on the VerifyNow P2Y12 test.
Abbreviations as in Figure 1.
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1173MACE rate, the assessment of OTR (due to its modest
sensitivity and speciﬁcity) is unlikely to have a prognostic
value (14,39). On the contrary, when dealing with the
high-risk population (including stable patients with DM
and/or CKD, and patients with acute coronary syndromes),
the assessment of OTR may have a relevant clinical beneﬁtTable 7. Univariate and Multivariate Cox Proportional Hazard Regression
for OTR- and CYP2C19-Based Predictive Tests in High-Risk Patients
High-Risk Subset
Univariate Model Multivariate Model
HR 95% CI p Value HR 95% CI p Value
High OTR* Diabetes mellitus 2.11 1.29–3.45 <0.00 2.40 1.48–4.20 0.03
CKD 2.03 1.03–4.02 0.04 2.09 1.01–4.67 0.04
CYP2C19
variantsy
Diabetes mellitus 1.98 1.08–3.64 0.02 1.45 1.01–3.12 0.01
CKD 1.55 1.06–2.27 0.02 2.00 1.21–3.10 <0.00
For the adjusted p values, bootstrap sampling method (1,000 reps) was employed. *On-
treatment platelet reactivity, assessed by the VerifyNow P2Y12 test (P2Y12 reaction units 230).
yComposite of CYP2C19 variants: CYP2C19*2 (681 G>A), CYP2C19*3 (636 G>A), CYP2C19*4
(1 A>G), CYP2C19*5 (1,297 C>T), and CYP2C19*17 (806 C>T).
Abbreviations as in Tables 1, 3, and 5.(40–43). This interpretation explains why, for example, in
the ADAPT-DES (Assessment of Dual Antiplatelet Ther-
apy with Drug-Eluting Stents) trial, the OTR (assessed with
the VerifyNow P2Y12 test) was a strong independent pre-
dictor of stent thrombosis at 30 days only in patients with
acute coronary syndromes but not in patients with stable
CAD (39). This result has been recently conﬁrmed (44). The
POPULAR (Do Platelet Function Assays Predict Clinical
Outcomes in Clopidogrel-Pretreated Patients Undergoing
Elective PCI) trial demonstrated a modest accuracy of 4
platelet reactivity tests (including the VerifyNow P2Y12 test)
in predicting clinical outcome (43). Possible explanations
for the discrepancy between our study and the POPULAR
trial are: 1) differences in the risk at baseline of the patient
populations (as suggested by the different rate of DM,
CKD, and bifurcation lesions); and 2) differences in the type
of stent used in the 2 studies. Indeed, the extensive use of
second-generation DES in our study may have had a relevant
role in reducing the MACE rate at follow-up. As recently
reported, when comparedwith ﬁrst-generationDES, second-
generation DES are associated with a 43% lower risk of
deﬁnite stent thrombosis and with a 23% lower risk of death
for up to 2 years (45). Finally, our interpretation may also
explain the negative ﬁndings of some recent trials that aimed
to demonstrate a clinically relevant effect of an antiplatelet
therapy tailored according to the OTR result. Indeed,
the strategies of increasing the clopidogrel maintenance dose
(14) and of switching to prasugrel (46,47) in patients with
high OTR failed to improve clinical outcome.
Study limitations. The results of the present study should be
limited to the boundaries of the functional assay used (i.e.,
the VerifyNow P2Y12 test) and cannot be directly extended
to other clinical assays proposed to assess OTR (48,49). At
present, there is no standardized procedure, due to signi-
ﬁcant variability among the methods and the absence of
uniform cutoff values for identifying patients at higher
risk. In addition, the optimal timing for platelet function
testing (that is, whether on admission, just before or after
surgery, or weeks after discharge) has not been assessed. Some
evidence does exist on the superiority of measuring platelet
function at 1 month after intervention (50), but other trials
are required to better clarify the position of routine assessment
of platelet assays in clinical practice. Lack of exact timing
between the last clopidogrel maintenance dose and the Ver-
ifyNow test assessment may represent a further limitation.
However, it is unlikely that a <3-h interval may have had an
impact on the VerifyNow test result. The results in high-risk
patients represent a subgroup analysis of a registry. There-
fore, this ﬁnding should be tested in speciﬁcally designed
randomized controlled trials. Moreover, the observed 7.9%
MACE rate was lower than that hypothesized; this might
make our study slightly underpowered. However, the ob-
served MACE rate was in the range of the 95% conﬁdence
interval of the expected incidence (adjusted Wald interval:
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11743.6% to 13%). The baseline and procedural characteristics of
our patient cohort may explain the high stent thrombosis rate.
Compared with those in other studies, our cohort had greater
incidences of DM, CKD, and bifurcation lesions. Finally,
the cost-effectiveness of routine genotyping and residual
platelet function testing procedures, as well as their thera-
peutic impact, were not studied and should be further
investigated.Conclusions
Routine assessment of CYP2C19 polymorphisms can be
used to risk stratify stable CAD patients receiving DES,
whereas routine assessment of OTR with the VerifyNow
P2Y12 test has a predictive value only in high-risk stable
CAD patients, such as those with DM or CKD. Ran-
domized controlled trials are warranted to address whether:
1) antiplatelet therapy guided by genetic testing demon-
strates a clinically relevant effect in all patients with stable
CAD treated by DES implantation; and 2) antiplatelet
therapy guided by OTR testing alone or in combination
with genetic testing has a clinically relevant effect in diabetic
and CKD patients with stable CAD treated by DES
implantation.
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